Literature DB >> 33761934

Discovery of LAMP-2A as potential biomarkers for glioblastoma development by modulating apoptosis through N-CoR degradation.

Yongjie Wang1, Buyi Zhang2, Jianli Wang1, Haijian Wu1, Shenbin Xu1, Jianmin Zhang3, Lin Wang4.   

Abstract

BACKGROUND: Lysosome-associated membrane protein type 2A (LAMP-2A) is the key component of chaperone-mediated autophagy (CMA), a cargo-selective lysosomal degradation pathway. Aberrant LAMP-2A expression and CMA activation have been demonstrated in various human malignancies. The study focusing on the intrinsic role of LAMP-2A and CMA in glioblastoma (GBM), and downstream mechanism could provide valuable insight into the pathogenesis and novel therapeutic modality of GBM.
METHODS: The levels of LAMP-2A, nuclear receptor co-repressor (N-CoR), unfolded protein response (UPR) and apoptosis were examined in clinical samples. LAMP-2A siRNA and shRNA were constructed to manipulate CMA activation. The role of CMA and downstream mechanism through degradation of N-CoR and arresting UPR mediated apoptosis were explored in GBM cells and nude mouse xenograft model.
RESULTS: Elevated LAMP-2A and associated decreased N-CoR expression were observed in GBM as compared with peritumoral region and low-grade glioma. Inhibited UPR and apoptosis were observed in GBM with high LAMP-2A expression. In vitro study demonstrated co-localization and interaction between LAMP-2A and N-CoR. LAMP-2A silencing up-regulated N-CoR and aroused UPR pathway, leading to apoptosis, while N-CoR silencing led to an opposite result. In vivo study further confirmed that LAMP-2A inhibition arrested tumor growth by promoting apoptosis.
CONCLUSIONS: Our results demonstrated the central role of CMA in mediating N-CoR degradation and protecting GBM cells against UPR and apoptosis, and provided evidence of LAMP-2A as potential biomarker. Further research focusing on CMA with other tumorigenic process is needed and selective modulators of LAMP-2A remain to be investigated to provide a novel therapeutic strategy for GBM. Video Abstract.

Entities:  

Keywords:  Apoptosis; Chaperone-mediated autophagy; Glioblastoma; LAMP-2A; Nuclear receptor co-repressor; Unfolded protein response

Mesh:

Substances:

Year:  2021        PMID: 33761934      PMCID: PMC7992845          DOI: 10.1186/s12964-021-00729-8

Source DB:  PubMed          Journal:  Cell Commun Signal        ISSN: 1478-811X            Impact factor:   5.712


  37 in total

1.  Hypoxic stress activates chaperone-mediated autophagy and modulates neuronal cell survival.

Authors:  Eisuke Dohi; Shigeru Tanaka; Takahiro Seki; Tatsuhiro Miyagi; Izumi Hide; Tetsuya Takahashi; Masayasu Matsumoto; Norio Sakai
Journal:  Neurochem Int       Date:  2012-01-27       Impact factor: 3.921

Review 2.  Targeting the unfolded protein response in disease.

Authors:  Claudio Hetz; Eric Chevet; Heather P Harding
Journal:  Nat Rev Drug Discov       Date:  2013-09       Impact factor: 84.694

Review 3.  Autophagy and metabolism.

Authors:  Joshua D Rabinowitz; Eileen White
Journal:  Science       Date:  2010-12-03       Impact factor: 47.728

4.  LAMP2A overexpression in breast tumors promotes cancer cell survival via chaperone-mediated autophagy.

Authors:  Tapas Saha
Journal:  Autophagy       Date:  2012-08-09       Impact factor: 16.016

5.  Chaperone-mediated autophagy degrades mutant p53.

Authors:  Helin Vakifahmetoglu-Norberg; Minsu Kim; Hong-Guang Xia; Marcin P Iwanicki; Dimitry Ofengeim; Jonathan L Coloff; Lifeng Pan; Tan A Ince; Guido Kroemer; Joan S Brugge; Junying Yuan
Journal:  Genes Dev       Date:  2013-08-01       Impact factor: 11.361

6.  The fusion oncoprotein PML-RARalpha induces endoplasmic reticulum (ER)-associated degradation of N-CoR and ER stress.

Authors:  Md Matiullah Khan; Teruaki Nomura; Tomoki Chiba; Keiji Tanaka; Hiderou Yoshida; Kazutoshi Mori; Shunsuke Ishii
Journal:  J Biol Chem       Date:  2003-12-29       Impact factor: 5.157

Review 7.  Crosstalk Between Macroautophagy and Chaperone-Mediated Autophagy: Implications for the Treatment of Neurological Diseases.

Authors:  Haijian Wu; Sheng Chen; Al-Baadani Ammar; Jie Xu; Qun Wu; Kum Pan; Jianmin Zhang; Yuan Hong
Journal:  Mol Neurobiol       Date:  2014-10-21       Impact factor: 5.590

8.  Downregulation of ATG5-dependent macroautophagy by chaperone-mediated autophagy promotes breast cancer cell metastasis.

Authors:  Qi Han; Youcai Deng; Sha Chen; Rui Chen; Mingzhen Yang; Zhujun Zhang; Xiongshan Sun; Wei Wang; Ying He; Fangjie Wang; Xiaodong Pan; Peng Li; Wenjing Lai; Hongqin Luo; Pei Huang; Xiao Guan; Yafei Deng; Jun Yan; Xianjie Xu; Yan Wen; An Chen; Chuanmin Hu; Xiaohui Li; Shuhui Li
Journal:  Sci Rep       Date:  2017-07-06       Impact factor: 4.379

9.  Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide.

Authors:  Alessia Lo Dico; Cristina Martelli; Cecilia Diceglie; Giovanni Lucignani; Luisa Ottobrini
Journal:  Front Oncol       Date:  2018-07-02       Impact factor: 6.244

10.  Glioblastoma ablates pericytes antitumor immune function through aberrant up-regulation of chaperone-mediated autophagy.

Authors:  Rut Valdor; David García-Bernal; Dolores Riquelme; Carlos M Martinez; Jose M Moraleda; Ana Maria Cuervo; Fernando Macian; Salvador Martinez
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-23       Impact factor: 11.205

View more
  2 in total

1.  Intercepting IRE1 kinase-FMRP signaling prevents atherosclerosis progression.

Authors:  Zehra Yildirim; Sabyasachi Baboo; Syed M Hamid; Asli E Dogan; Ozlem Tufanli; Sabrina Robichaud; Christina Emerton; Jolene K Diedrich; Hasan Vatandaslar; Fotis Nikolos; Yanghong Gu; Takao Iwawaki; Elizabeth Tarling; Mireille Ouimet; David L Nelson; John R Yates; Peter Walter; Ebru Erbay
Journal:  EMBO Mol Med       Date:  2022-02-22       Impact factor: 12.137

Review 2.  Modulating Chaperone-Mediated Autophagy and Its Clinical Applications in Cancer.

Authors:  Virginie Hubert; Sebastian Weiss; Andrew Jackson Rees; Renate Kain
Journal:  Cells       Date:  2022-08-17       Impact factor: 7.666

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.